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To the editor:  
Recently, in Clinical Pharmacology and Therapeutics, Kharasch et al [1] published a study 
on the role of CYP3A5 polymorphisms in the pharmacokinetics and pharmacodynamics of 
the CYP3A probe drugs alfentanil and midazolam, both CYP3A4 and CYP3A5 substrates. 
There was no relevant impact of CYP3A5 alleles *3, *6 and *7 on systemic or apparent oral 
clearances of alfentanil and midazolam, although these confer decreased CYP3A5 expression 
and activity.  
We assessed data on midazolam pharmacokinetics following semi-simultaneous 
administration of oral and i.v. midazolam, allowing for separate assessment of intestinal and 
hepatic CYP3A activity, from 59 healthy male volunteers and 30 HIV infected patients 
participating in six previously performed phenotyping studies (see Table 1) and related them 
to the main CYP3A5 polymorphism CYP3A5*3. 
All studies were approved by the ethics committee of the Medical Faculty of the University of 
Cologne and conducted in accordance with the Declaration of Helsinki, all participants gave 
their written informed consent. In all studies, oral and i.v. midazolam was given as a part of a 
phenotyping cocktail, whereas the other cocktail components varied between the respective 
studies (see Table 1). While in study A, the cocktail was given only once, in studies B - F 
(interaction studies), phenotyping was performed in two study periods, respectively, with and 
without co-medication.  
CYP3A5*3 genotyping was done via LightCycler® melting curve analysis (Primer R5'- 
TAgTTgTAGgACACACAgCAACC, Primer F5' - TTTgCCTCTTTgTACTTCTTCATC, 
Sensor 5'- gAgCTTTTTgTCTTTCAATATCTCT—FL, Anchor 5'- LC Red640-
CCCTgTTTggACCACATTACCCTT—PH). Midazolam in plasma was quantified by LC-
MS/MS [2]  
Total clearance (Cl) and intestinal availability (Fi) of midazolam, used as metrics of hepatic 
and intestinal CYP3A activity, respectively, were assessed by population analysis using 
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NONMEM software (V version 1.1, NONMEM Project Group, University of California at 
San Francisco, 1998). A two compartment model gave the best fit allowing for determination 
of Cl and oral bioavailability, whereas for calculation of Fi an additional equation was 
implemented [3].  
Results of the pharmacokinetic evaluation sorted by study and CYP3A5 genotype are shown 
in Table 1. CYP3A5 genotype was not a significant covariate neither for hepatic nor for 
intestinal CYP3A activity.  
Our results, derived upon a single phenotyping session with sequential midazolam 
administration allowing for a separate evaluation of both intestinal and hepatic CYP3A 
activity, which are independently regulated, confirm and expand the data by Kharasch et al. 
The clear inconsistency with respect to in vitro data showing a relevant effect of CYP3A5 
polymorphism on midazolam pharmacokinetics would suggest that, irrespective of CYP3A5 
genotype, the overall CYP3A5 plus 3A4 protein expression is relatively constant in both 
intestine and liver, and that relevant differences between CYP3A5 genotypes in vivo may 
occur only for substances which are metabolized more specifically by CYP3A5.  
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Table 1 
Characteristics of the phenotyping studies, results of CYP3A5*3 genotyping, and respective 
midazolam (M) pharmacokinetics.  
Pheno-
typing 
study 
Administration of  
midazolam (M) 
(other cocktail 
componentsa)  
study 
population 
Age 
 [years]  
BMI 
[kg/m2] 
CYP3A5*3 
genotype 
Total 
clearance of 
M [L/h] 
Intestinal 
availability 
of M [-] 
*1/3 N=2 22.60 0.84 A 1 mg i.v., then 1.5 mg 
orally 1.5 hours thereafter 
(Caff., Tol., Meph., Dex., 
Chlorz., Dig., Amox., Nic.) 
10 healthy 
male 
subjects 
30.9  
(25-40) 
24.6  
(21.2-27.0) *3/3 N=8 22.74  
(21.23-24.24) 
0.91 
(0.77-1.04) 
 
*1/1 N=1 27.30 0.70 
*1/3 N=4 28.18 
(23.02-33.33) 
0.48 
(0.40-0.56) 
B 2 mg orally, then 1 mg i.v. 
4 hours thereafter 
(Caff., Tol., Meph., Dex.) 
16 healthy 
male 
subjects 
29.3  
(23-42) 
23.5  
(21.5–26.6) 
*3/3 N=11 26.93 
(23.82-30.04) 
0.59 
(0.54-0.64) 
 
*1/3 N=1 19.46 0.25 C 2 mg orally, then 1 mg i.v. 
4 hours thereafter 
(Caff., Tol., Meph., Dex., 
Dig.) 
12 healthy 
male 
subjects 
38.0  
(24-49) 
24.5  
(20.0–29.3) 
*3/3 N=11 16.07 
(14.29-17.84) 
0.45 
(0.36-0.54) 
 
*1/3 N=2 21.80 0.40 D 2 mg orally, then 1 mg i.v. 
4 hours thereafter 
(Caff., Tol., Meph., Dex.) 
10 healthy 
male 
subjects 
29.7  
(22-43) 
24.1  
(20.4–27.8) 
*3/3 N=8 19.64 
(16.57-22.68) 
0.49 
(0.38-0.60) 
 
E 1.5 mg orally, then 1 mg  
i.v. 4 hours thereafter 
(Dex., Dig.) 
 
11 healthy 
male 
subjects 
30.6  
(18-48) 
22.3  
(20.2– 5.2) 
*3/3 N=11 27.47 
(21.38-33.57) 
0.75 
(0.63-0.88) 
*1/1 N=5 22.66 
(17.00-28.32) 
0.89 
(0.60-1.17) 
*1/3 N=8 24.33 
(19.85-28.80) 
1.13 
(0.90-1.35) 
F 1.5 mg orally, then 1 mg  
i.v. 4 hours thereafter 
(Dex., Dig.) 
30 HIV-
positive 
patients (23 
male and 7 
female) 
39.9  
(25-60) 
23.5  
(16.4–36.7) 
*3/3 N=17 26.06 
(22.99-29.13) 
1.10 
(0.95-1.26) 
*1/1 N=6 23.43 
(18.17-28.70) 
0.86 
(0.58-1.13) 
*1/3 N=17 24.45 
 (21.32-27.57) 
0.80  
(0.64-0.97) 
Total  89 subjects 
(69 healthy 
male 
subjects and 
30 HIV-
positive 
patients) 
34.4  
(18-60) 
23.7  
(16.4–36.7) 
*3/3 N=66 23.60  
(22.00-25.18) 
0.75 
 (0.67-0.84) 
Demographic data (determined at the screening examination) are given as mean and (range); 
pharmacokinetics is given as mean and (95% confidence interval). For studies with two 
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periods (B - F), the pharmacokinetic parameters were calculated in the periods without co-
medication. Confidence interval was calculated if N>3 
aCocktail components: Caff. – caffeine, Tol. - tolbutamide, Meph. - mephenytoin, Dex. - 
dextromethorphan, Chlorz. - chlorzoxazone, Dig. - digoxin, Amox. - amoxicillin, Nic. - 
nicotine 
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